CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The brand has added a range of exciting new products especially formulated for oily skin.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Subscribe To Our Newsletter & Stay Updated
